Published in Histochem J on February 01, 1990
Rat intestinal mucosal responses to a microbial flora and different diets. Gut (1995) 1.10
The interaction of large bowel microflora with the colonic mucus barrier. Int J Inflam (2010) 0.82
Transport of particles in intestinal mucus under simulated infant and adult physiological conditions: impact of mucus structure and extracellular DNA. PLoS One (2014) 0.77
Immune-driven alterations in mucin sulphation is an important mediator of Trichuris muris helminth expulsion. PLoS Pathog (2017) 0.75
Random amplified polymorphic DNA assay is less discriminant than pulsed-field gel electrophoresis for typing strains of methicillin-resistant Staphylococcus aureus. J Clin Microbiol (1993) 3.21
Distribution of erythromycin esterase and rRNA methylase genes in members of the family Enterobacteriaceae highly resistant to erythromycin. Antimicrob Agents Chemother (1987) 2.80
Duration of colonization by methicillin-resistant Staphylococcus aureus after hospital discharge and risk factors for prolonged carriage. Clin Infect Dis (2001) 2.48
Emergence and spread in French hospitals of methicillin-resistant Staphylococcus aureus with increasing susceptibility to gentamicin and other antibiotics. J Clin Microbiol (1999) 2.12
Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol (1988) 2.00
Effect of erythromycin on microbial antagonisms: a study in gnotobiotic mice associated with a human fecal flora. J Infect Dis (1983) 1.90
Plasmid-mediated high-level resistance to erythromycin in Escherichia coli. Antimicrob Agents Chemother (1986) 1.72
Inducible transfer of conjugative transposon Tn1545 from Enterococcus faecalis to Listeria monocytogenes in the digestive tracts of gnotobiotic mice. Antimicrob Agents Chemother (1991) 1.68
Prospective multicenter study of vascular-catheter-related complications and risk factors for positive central-catheter cultures in intensive care unit patients. J Clin Microbiol (1990) 1.56
Risk factors for candidemia in patients with acute lymphocytic leukemia. Rev Infect Dis (1991) 1.51
Reduction of the aerobic Gram negative bacterial flora of the gastro-intestinal tract and prevention of traveller's diarrhea using oral erythromycin. Ann Microbiol (Paris) (1982) 1.48
Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int J Antimicrob Agents (2000) 1.48
Prevalence of virulence genes and clonality in Escherichia coli strains that cause bacteremia in cancer patients. Infect Immun (2000) 1.47
Earlier positivity of central-venous- versus peripheral-blood cultures is highly predictive of catheter-related sepsis. J Clin Microbiol (1998) 1.42
Candidemia in French hospitals: incidence rates and characteristics. Clin Microbiol Infect (2002) 1.42
Comparison of ribotyping, pulsed-field gel electrophoresis and random amplified polymorphic DNA for typing Clostridium difficile strains. FEMS Microbiol Lett (1994) 1.40
Random amplified polymorphic DNA typing versus pulsed-field gel electrophoresis for epidemiological typing of vancomycin-resistant enterococci. J Clin Microbiol (1996) 1.35
Decontamination of polymerase chain reaction reagents for detection of low concentrations of 16S rRNA genes. Mol Biotechnol (1997) 1.34
Selective antimicrobial modulation of the intestinal tract by norfloxacin in human volunteers and in gnotobiotic mice associated with a human fecal flora. Antimicrob Agents Chemother (1986) 1.31
Epidemiology of intestinal colonization by members of the family Enterobacteriaceae highly resistant to erythromycin in a hematology-oncology unit. Antimicrob Agents Chemother (1986) 1.30
Detection of genes in feces by booster polymerase chain reaction. J Clin Microbiol (1992) 1.20
Plasmid-mediated susceptibility to intestinal microbial antagonisms in Escherichia coli. Infect Immun (1985) 1.19
Pseudoepidemic of aspergillosis after development of pulmonary infiltrates in a group of bone marrow transplant patients. J Clin Microbiol (1987) 1.14
Investigation of the potential role of Enterococcus faecalis in the pathophysiology of experimental peritonitis. J Infect Dis (1994) 1.11
Rapid control of an outbreak of vancomycin-resistant enterococci in a French university hospital. J Hosp Infect (2007) 1.11
Genetic diversity of Pseudomonas aeruginosa strains isolated from ventilated patients with nosocomial pneumonia, cancer patients with bacteremia, and environmental water. Infect Immun (2001) 1.11
Treatment of experimental salmonellosis in mice with ampicillin-bound nanoparticles. Antimicrob Agents Chemother (1989) 1.08
Effect of oral ofloxacin on fecal bacteria in human volunteers. Antimicrob Agents Chemother (1987) 1.07
Effectiveness of simple measures to control an outbreak of nosocomial methicillin-resistant Staphylococcus aureus infections in an intensive care unit. Infect Control Hosp Epidemiol (1990) 1.07
Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. J Natl Cancer Inst (1996) 1.06
Characterization of AfaE adhesins produced by extraintestinal and intestinal human Escherichia coli isolates: PCR assays for detection of Afa adhesins that do or do not recognize Dr blood group antigens. J Clin Microbiol (2001) 1.06
Conjugal transfer of plasmid DNA from Enterococcus faecalis to Escherichia coli in digestive tracts of gnotobiotic mice. Antimicrob Agents Chemother (1992) 1.01
Genesis of a KPC-producing Klebsiella pneumoniae after in vivo transfer from an imported Greek strain. Euro Surveill (2010) 1.01
Trichoderma pseudokoningii as a cause of fatal infection in a bone marrow transplant recipient. Clin Infect Dis (1995) 1.00
Comparative translocation of enteropathogenic Campylobacter spp. and Escherichia coli from the intestinal tract of gnotobiotic mice. Infect Immun (1987) 0.99
Use of beta-lactamase-producing anaerobes to prevent ceftriaxone from degrading intestinal resistance to colonization. J Infect Dis (1989) 0.99
Effectiveness of nanoparticle-bound ampicillin in the treatment of Listeria monocytogenes infection in athymic nude mice. Antimicrob Agents Chemother (1988) 0.97
Liposomes and nanoparticles in the treatment of intracellular bacterial infections. Pharm Res (1991) 0.95
Heterogeneity of genes conferring high-level resistance to erythromycin by inactivation in enterobacteria. Ann Inst Pasteur Microbiol (1988) 0.95
Epidemiology of intestinal colonization by members of the family Enterobacteriaceae resistant to cefotaxime in a hematology-oncology unit. Antimicrob Agents Chemother (1986) 0.93
Faecal excretion of ciprofloxacin after a single oral dose and its effect on faecal bacteria in healthy volunteers. J Antimicrob Chemother (1990) 0.92
Hand contamination before and after different hand hygiene techniques: a randomized clinical trial. J Hosp Infect (2002) 0.91
Presence of Clostridium difficile and antibiotic and beta-lactamase activities in feces of volunteers treated with oral cefixime, oral cefpodoxime proxetil, or placebo. Antimicrob Agents Chemother (1992) 0.91
Clinical predictive values of extended-spectrum beta-lactamase carriage in patients admitted to medical wards. Eur J Clin Microbiol Infect Dis (2011) 0.91
Effects of roxithromycin on fecal bacteria in human volunteers and resistance to colonization in gnotobiotic mice. Antimicrob Agents Chemother (1991) 0.90
Development of ciprofloxacin-loaded nanoparticles: physicochemical study of the drug carrier. J Control Release (1998) 0.88
Acquisition of carbapenemase-producing Enterobacteriaceae by healthy travellers to India, France, February 2012 to March 2013. Euro Surveill (2014) 0.88
Shedding of antibiotic-resistant members of the family Enterobacteriaceae in healthy residents of France and Jordan. Res Microbiol (1995) 0.87
Streptococcal septicaemia following autologous bone marrow transplantation in children treated with high-dose chemotherapy. Bone Marrow Transplant (1991) 0.87
In vivo activity of nifurzide and nifuroxazide in intestinal bacteria in man and gnotobiotic mice. J Appl Bacteriol (1985) 0.87
Single-step polymerase chain reaction for combined gene detection and epidemiological typing in three bacterial models. FEMS Microbiol Lett (1997) 0.87
Resistance to methicillin and virulence of Staphylococcus aureus strains in bacteriemic cancer patients. Intensive Care Med (1993) 0.87
In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study. Clin Microbiol Infect (2003) 0.86
Ampicillin-loaded liposomes and nanoparticles: comparison of drug loading, drug release and in vitro antimicrobial activity. J Microencapsul (1991) 0.86
Kinetics of Saccharomyces cerevisiae elimination from the intestines of human volunteers and effect of this yeast on resistance to microbial colonization in gnotobiotic mice. Appl Environ Microbiol (1991) 0.86
Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647). Antimicrob Agents Chemother (2001) 0.86
Production of haemolysin, aerobactin and enterobactin by strains of Escherichia coli causing bacteraemia in cancer patients, and their resistance to human serum. Res Microbiol (1989) 0.86
[Comparison between the number and nature of fecal clostridia and other risk factors implicated in the intestinal pathology of newborn infants]. Ann Inst Pasteur Microbiol (1988) 0.85
Antimicrobial agent exposure and the emergence and spread of resistant microorganisms: issues associated with study design. Eur J Clin Microbiol Infect Dis (2012) 0.85
"Intestinal spirochaetosis" of the vervet monkey. Onderstepoort J Vet Res (1985) 0.84
Impact of quinupristin/dalfopristin (RP59500) on the faecal microflora in healthy volunteers. J Antimicrob Chemother (2002) 0.84
Liposome-entrapped ampicillin in the treatment of experimental murine listeriosis and salmonellosis. Antimicrob Agents Chemother (1991) 0.83
Activity and specificity of a mouse monoclonal antibody to ferric aerobactin. Infect Immun (1992) 0.83
Flucytosine conversion to fluorouracil in humans: does a correlation with gut flora status exist? A report of two cases using fluorine-19 magnetic resonance spectroscopy. Infection (1991) 0.82
Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres. Infect Immun (1997) 0.81
Introduction of highly resistant bacteria into a hospital via patients repatriated or recently hospitalized in a foreign country. Clin Microbiol Infect (2014) 0.81
Intranasal immunization with protein-linked phosphorylcholine protects mice against a lethal intranasal challenge with streptococcus pneumoniae. Vaccine (2000) 0.81
[Effect of erythromycin on the populations of enterobacteria in the human digestive tract]. Nouv Presse Med (1980) 0.81
Intracellular distribution of ampicillin in murine macrophages infected with Salmonella typhimurium and treated with (3H)ampicillin-loaded nanoparticles. J Antimicrob Chemother (1996) 0.81
Mucosal immunogenicity elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly (D,L-lactide-co-glycolide) microspheres. Vaccine (1998) 0.80
Shedding of Clostridium difficile, fecal beta-lactamase activity, and gastrointestinal symptoms in 51 volunteers treated with oral cefixime. Antimicrob Agents Chemother (1993) 0.80
Non-nephrotoxic empiric antimicrobial therapy in febrile neutropenic cancer patients. Eur J Cancer (1992) 0.80
Immunological variants of the aerobactin-cloacin DF13 outer membrane protein receptor IutA among enteric bacteria. Infect Immun (1994) 0.79
Systemic lupus erythematosus-associated catastrophic antiphospholipid syndrome occurring after typhoid fever: a possible role of Salmonella lipopolysaccharide in the occurrence of diffuse vasculopathy-coagulopathy. Arthritis Rheum (1999) 0.79
Evaluation of growth promotion and inhibition from mycobactins and nonmycobacterial siderophores (Desferrioxamine and FR160) in Mycobacterium aurum. Antimicrob Agents Chemother (1997) 0.78
Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients. J Antimicrob Chemother (1998) 0.78
Comparison of chemical assay, bioassay, enzyme-linked immunosorbent assay, and dot blot hybridization for detection of aerobactin in members of the family Enterobacteriaceae. Appl Environ Microbiol (1993) 0.78
The uptake of ampicillin-loaded nanoparticles by murine macrophages infected with Salmonella typhimurium. J Antimicrob Chemother (1994) 0.77
Energy state in HT-29 cells is linked to differentiation. In Vitro Cell Dev Biol Anim (1997) 0.77
Severe gram-negative infections in neutropenic children cured by imipenem/cilastatin in combination with an aminoglycoside. J Antimicrob Chemother (1986) 0.76
[Antibiotic strategy for febrile episodes during severe (less than 500 PNN) and prolonged (greater than or equal to 7 days) neutropenia. Recommendations of the Evaluation Committee of the Collège Français des Hematologistes]. Nouv Rev Fr Hematol (1994) 0.76
Effects of bacterial colonization on mucosal structure of the large bowel of neonatal rats. Acta Anat (Basel) (1988) 0.76
Results of passive and active immunization directed against ferric aerobactin in experimental enterobacterial infections in mice and chickens. Res Microbiol (1995) 0.76
Effect of steroid hormones on membrane profiles of HeLa S3 cells. Cell Biol Int (2001) 0.76
Intracellular visualization of ampicillin-loaded nanoparticles in peritoneal macrophages infected in vitro with Salmonella typhimurium. Pharm Res (1994) 0.76
In vivo fate and immune pulmonary response after nasal administration of microspheres loaded with phosphorylcholine-thyroglobulin. Int J Pharm (1999) 0.76
[Evaluation of initial antibiotic therapy for bacteremia and role of an antibiotic management team for antibiotic stewardship]. Med Mal Infect (2010) 0.76
Secular trends and dynamics of hospital associated methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect (2010) 0.76
The emergence of linezolid resistance among Enterococci in intestinal microbiota of treated patients is unrelated to individual pharmacokinetic characteristics. Antimicrob Agents Chemother (2014) 0.75
Evaluating and predicting the ecologic impact of antibiotics. Clin Microbiol Infect (2001) 0.75
Drug targeting by polyalkylcyanoacrylate nanoparticles is not efficient against persistent Salmonella. Pharm Res (1998) 0.75
Experimental intestinal microflora in mice with a changeable population size of E. coli. Prog Clin Biol Res (1985) 0.75
Synthesis and in vitro antibacterial activity of catechol-spiramycin conjugates. J Antibiot (Tokyo) (1998) 0.75
[Cholera in a Paris resident with no history of travel. A case report]. Presse Med (1998) 0.75
[The use of nano-particles for the vectorization of antibiotic and antineoplastic drugs]. Bull Mem Acad R Med Belg (1988) 0.75
The influence of colonizing micro-organisms on development of crypt architecture in the neonatal mouse colon. Acta Anat (Basel) (1990) 0.75
[Value of the combination of piperacillin and pefloxacin possibly followed by vancomycin in the treatment of febrile neutropenia in nephrotoxic chemotherapy]. Bull Cancer (1992) 0.75
Totally implanted catheters to reduce catheter-related infections in patients receiving interleukin-2: a 2-year experience. Support Care Cancer (1995) 0.75
Measurement of inhibition zone diameter in disk susceptibility tests by computerized image analysis. Comput Biol Med (1994) 0.75